In a report released today, Suraj Kalia from Northland Securities maintained a Sell rating on Sensus Healthcare Inc (SRTS), with a price target of $5. The company’s shares opened today at $8.25, close to its 52-week high of $8.88.
Kalia observed:
“We note that we were not allowed to ask questions on the call, hence we raise several questions in this note. Company commentary does not provide the adequate picture, for the reasons mentioned underneath. Maintain UP / $5 PT.”
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 12.3% and a 56.9% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Strata Skin Sciences Inc, and Obalon Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Sensus Healthcare Inc with a $9.75 average price target.
See today’s analyst top recommended stocks >>
Based on Sensus Healthcare Inc’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $458.1K. In comparison, last year the company had a GAAP net loss of $408.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sensus Healthcare, Inc. engages in the design, manufacture, and marketing of proprietary medical devices specializing in the treatment of non-melanoma skin cancers and other skin conditions. Its main product is SRT-100, a photon x-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating basal cell and squamous cell skin cancers and other skin conditions such as keloids. The company was founded by Joseph C. Sardano, Richard Golin, Kalman Fishman and Stephen Cohen on May 7, 2010 and is headquartered in Boca Raton, FL.
